Literature DB >> 11119258

Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: comparison with the MHC-tetramer technology.

M Oelke1, T Kurokawa, I Hentrich, D Behringer, V Cerundolo, A Lindemann, A Mackensen.   

Abstract

Cell therapy with antigen-specific T cells holds promise for various diseases including cancer and viral infections. The powerful enrichment procedure based on major histocompatibility complex (MHC)-tetramers, however, is of limited applicability so far. Therefore, the recently developed cell surface affinity matrix technology that allows direct identification and enrichment of life antigen-specific T cells based on cytokine secretion was evaluated in this respect. To this end, CD8(+) T cells directed against the HLA-A(*)0201-restricted melanoma-associated peptide Melan-A (aa26-35) were generated by combining stimulation of peptide-pulsed autologous dendritic cells (DC) with antigen-independent expansion with anti-CD3/anti-CD28 monoclonal antibodies (MoAb). Antigen-specific cytotoxic T lymphocyte (CTL) were detected based on stimulation-induced interferon (IFN)-gamma and interleukin (IL)-4 secretion and enriched > 100-fold using the cell surface affinity matrix technology. The resulting IFN-gamma- and IL-4-secreting CTL lines contained > 80% and > 70% cytokine positive T cells, respectively. They exhibited a cytotoxic activity against Melan-A expressing target cells that was significantly higher as compared to nonpurified CTL. Direct staining of enriched CTL with HLA-A2-Melan-A-tetramers revealed a high correlation between the results obtained from the cell surface affinity matrix technology and those obtained from tetrameric complexes. Altogether, our study demonstrates that cytokine-driven enrichment based on the cell surface affinity matrix technology enables selective isolation of functionally active antigen-specific CTL that may be used for an adoptive T cell transfer in immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11119258     DOI: 10.1046/j.1365-3083.2000.00810.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.

Authors:  Benjamin J D Weist; Patrizia Wehler; Linda El Ahmad; Michael Schmueck-Henneresse; Jason M Millward; Mikalai Nienen; Avidan U Neumann; Petra Reinke; Nina Babel
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

2.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

3.  Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development.

Authors:  Darío Lirussi; Thomas Ebensen; Kai Schulze; Elena Reinhard; Stephanie Trittel; Peggy Riese; Blair Prochnow; Carlos A Guzmán
Journal:  J Vis Exp       Date:  2018-06-19       Impact factor: 1.355

4.  Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.

Authors:  Lara Kristina Klauer; Olga Schutti; Selda Ugur; Fatemeh Doraneh-Gard; Daniel Christoph Amberger; Nicole Rogers; Doris Krämer; Andreas Rank; Christoph Schmid; Britta Eiz-Vesper; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2021-07-07       Impact factor: 3.747

5.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

6.  Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.

Authors:  Jan B Boscheinen; Sabrina Thomann; David M Knipe; Neal DeLuca; Beatrice Schuler-Thurner; Stefanie Gross; Jan Dörrie; Niels Schaft; Christian Bach; Anette Rohrhofer; Melanie Werner-Klein; Barbara Schmidt; Philipp Schuster
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

7.  Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.

Authors:  Yuanxin Xu; Valerie Theobald; Crystal Sung; Kathleen DePalma; Laura Atwater; Keirsten Seiger; Michael A Perricone; Susan M Richards
Journal:  J Transl Med       Date:  2008-10-22       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.